-
Preliminary data indicate that the prevalence of influenza A (H1N1) virus strains resistant to the antiviral medication oseltamivir is high. Therefore, interim guidelines issued by the CDC are to use zanamivir or a combination of oseltamivir and rimantidine if influenza A (H1N1) infection is suspected.
-
Nucleic acid amplification (NAA) testing should be performed on at least one respiratory specimen from each patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered but has not yet been established, and for whom the test result would alter case management or TB control activities.
-
Your next patient is an adolescent female who has requested immunization with the vaccine for human papillomavirus (HPV). When she asks specifically about the vaccine's safety, what can you tell her?
-
The next patient in your exam room is a 17-year-old female who uses the contraceptive injection depot medroxyprogesterone acetate (DMPA) for birth control.
-
Research findings presented at a February 2009 international conference indicate that an investigational gel known as PRO 2000 (Indevus Pharmaceuticals; Lexington, MA) proved about 30% effective in preventing HIV infection in women.
-
-
Reproductive health advocates are throwing their support behind the Obama administration's move to rescind a controversial "conscience" rule that would expand the right of health care personnel and institutions to refuse to provide or assist in the provision of services on moral or religious grounds.
-
Today, women account for more than one-quarter of all new HIV/AIDS diagnoses in the United States, according to the Centers for Disease Control and Prevention.
-
Access barriers to the dedicated emergency contraceptive pill (ECP) Plan B are set to be lifted. A federal judge has instructed the Food and Drug Administration (FDA) to make Plan B available to 17-year-olds and ordered the agency to review whether to make the ECP available to females 17 and under without prescription.
-
Utilizing genotyping for warfarin therapy in patients with non-valvular atrial fibrillation may not be cost-effective.